Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens

Nucleophosmin-1 mutations (NPM1(+)) occur in ∼30% of acute myeloid leukemia (AML) patients. Although typically associated with favorable prognosis, the beneficial impact of NPM1(+) decreases with increasing age in patients treated with standard intensive chemotherapy (IC) or hypomethylating agents (...

Full description

Saved in:
Bibliographic Details
Published in:Blood Adv
Main Authors: Lachowiez, Curtis A., Loghavi, Sanam, Kadia, Tapan M., Daver, Naval, Borthakur, Gautam, Pemmaraju, Naveen, Naqvi, Kiran, Alvarado, Yesid, Yilmaz, Musa, Short, Nicholas, Ohanian, Maro, Pierce, Sherry R., Patel, Keyur P., Qiao, Wei, Ning, Jing, Sasaki, Koji, Takahashi, Koichi, Jabbour, Elias, Andreeff, Michael, Ravandi, Farhad, Kantarjian, Hagop M., Konopleva, Marina, DiNardo, Courtney D.
Format: Artigo
Language:Inglês
Published: American Society of Hematology 2020
Subjects:
Myeloid Neoplasia
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7160266/
https://ncbi.nlm.nih.gov/pubmed/32251497
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019001267
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items